- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02861846
Predictive Value of Biomarkers of the Alzheimer's Disease (AD) in Elderly Patients With New-onset Epilepsy (BIOMALEPSIE)
Beyond 60 years, the prevalence of epilepsy is estimated at approximately 1% and increases with age. In these patients, the etiology of epilepsy is unknown in 25% of cases, even up to 55% after 65 years. Although new-onset epilepsy in the elderly is associated with a vascular disease in 50% of cases, the hypothesis of an ongoing neurodegenerative process, including an Alzheimer's disease (AD), is also common. However, investigators do not have any marker that might help to identify the patients who develop epilepsy after 60 years and who might be, despite a normal cognitive functioning, already engaged in the pathophysiological process of AD.
A number of data suggest a link between the pathophysiological process of AD and epileptogenesis:
(i) a third of patients with epilepsy develops MA, (ii) the occurrence of epilepsy in AD is an aggravating factor for cognition, (iii) in animal models of AD, the relationship between neuronal hyperexcitability and amyloid deposits is bidirectional, the amyloid protein has a pro-seizure effect and the presence of epilepsy increases the amyloid deposits, (iv) in these models, the administration of an antiepileptic drug protects from deterioration of cognition, (v) the close relationship between amyloid and neuronal hyperexcitability might be mediated by the inflammatory processes associated with AD, and particularly the microglial activation which role in epileptogenesis has been shown elsewhere.
Investigators hypothesize that in a subgroup of patients who develop epilepsy after 60 years, the occurrence of epilepsy might reflect the presence of an ongoing amyloid pathology. Our goal is to identify through biomarkers of AD in the cerebrospinal fluid of patients who develop an epilepsy after 60 years with normal MRI and normal cognition those at high risk of later developing clinically defined AD.
Identifying patients with amyloid pathology which would be expressed through epilepsy before the onset of cognitive dysfunction might help to adapt both the management of seizures and of the cognitive dysfunction.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bron, France, 69500
- Hospices Civils de Lyon
-
Clermont-Ferrand, France
- CHU Gabriel- Montpied
-
Grenoble, France
- CHU des Alpes
-
Saint-Étienne, France
- CHU Hôpital Nord
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 60 years
- Patients with newly diagnosed epilepsy according to the latest criteria of the International League against Epilepsy.
- MMSE ≥ 28/30.
- Patients with or without cognitive complaints.
- Patients whose brain MRI did not reveal significant abnormalities outside slight cortical atrophy.
- Patients in whom the lumbar puncture did not revealed abnormalities suggestive of an infectious disease or a limbic encephalitis.
- Patient with adequate visual and auditory skills, an oral and written language in French available to clinical and neuropsychological assessment.
- Patient who have given its written consent.
Exclusion Criteria:
- Previous history of epilepsy before age 60 years.
- Patient with against-indication to MRI (pacemaker, ferromagnetic clips, mechanical heart valves, intra-cochlear implants, intraocular foreign body, skin or other) or refusing MRI.
- Presence of an abnormality in brain MRI.
- Patients with diagnostic criteria for dementia of Alzheimer's disease, vascular dementia, mixed dementia or frontotemporal lobar degeneration.
- Patients with autoimmune encephalitis.
- Patients under legal protection measure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Presence of biomarkers of AD in cerebrospinal fluid
Patients older than 60 years, with normal brain MRI and with normal cognitive functioning who demonstrate a profile of CSF biomarkers of AD suggestive of biological AD
|
dosage of biomarker of AD
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary endpoint was the number of patients in a population of subjects older than 60 years with new-onset epilepsy but without cognitive impairment whose profile of the CSF biomarkers of the AD is suggestive of an AD.
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
changes in episodic verbal memory at 2 years
Time Frame: 2 years
|
Evolution of RL/RI-16 score between inclusion and 2 years of follow-up
|
2 years
|
changes in visual recognition memory at 2 years
Time Frame: 2 years
|
Evolution of DMS 48 score between inclusion and 2 years of follow-up
|
2 years
|
Evolution of DO 80 score
Time Frame: 2 years
|
Evolution of semantic memory at 2 years: Evolution of DO 80 score between inclusion and 2 years follow-up
|
2 years
|
Evolution of categorical influences
Time Frame: 2 years
|
Evolution of semantic memory at 2 years: Evolution of categorical influences between inclusion and 2 years follow-up
|
2 years
|
Evolution of TOP 10 score
Time Frame: 2 years
|
Evolution of semantic memory at 2 years: Evolution of TOP 10 score between inclusion and 2 years follow-up
|
2 years
|
Changes in monthly frequency of seizures at 2 years
Time Frame: 2 years
|
Evolution of monthly frequency of seizures between inclusion and 2 years of follow-up
|
2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Aurélie RICHARD-MORNAS, Doctor, Hospices Civils de Lyon
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 69HCL16-0041
- 2016-A00563-48 (Other Identifier: ID-RCB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsy
-
NaviFUS CorporationTaipei Veterans General Hospital, TaiwanCompletedDrug Resistant Epilepsy | Epilepsy, Drug Resistant | Intractable Epilepsy | Refractory Epilepsy | Drug Refractory Epilepsy | Epilepsy, Drug Refractory | Epilepsy, Intractable | Medication Resistant EpilepsyTaiwan
-
Great Ormond Street Hospital for Children NHS Foundation...Active, not recruitingEpilepsies, Partial | Intractable Epilepsy | Focal Epilepsy | Refractory Epilepsy | Epilepsy Intractable | Epilepsy in Children | Epilepsy, FocalUnited Kingdom
-
University of British ColumbiaTerminatedJuvenile Myoclonic Epilepsy | Childhood Absence Epilepsy | Juvenile Absence EpilepsyCanada
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
Neuroelectrics CorporationRecruitingEpilepsy | Seizures | Refractory Epilepsy | Epilepsy, Tonic-Clonic | Epilepsy in Children | Seizures, Focal | Focal SeizureSpain, United States, France, Belgium
-
Oslo University HospitalCompletedEpilepsy | Generalized Epilepsy | Focal EpilepsyNorway
-
UCB Pharma SACompletedEpilepsy, Tonic-clonicPoland, Sweden, Hungary, Czechia
-
UCB PharmaCompletedEpilepsy, Tonic-clonic
-
Xuanwu Hospital, BeijingPeking University; Beijing Tiantan Hospital; Qilu Hospital of Shandong University and other collaboratorsNot yet recruitingEpilepsy, Drug ResistantChina
-
University Hospital, LilleUnknownFocal Epilepsy | Epilepsy IntractableFrance
Clinical Trials on profile of CSF biomarkers of AD
-
Aristotle University Of ThessalonikiRecruitingCardiovascular Diseases | Heart Failure | Valvular Heart Disease | Biochemical DysfunctionGreece
-
University of UtahCompletedIntraventricular Hemorrhage | Premature InfantsUnited States
-
Samus Therapeutics, Inc.TerminatedAlzheimer DiseaseUnited States
-
Addpharma Inc.Not yet recruitingHypertension,Essential
-
Addpharma Inc.Completed
-
Zhejiang Hisun Pharmaceutical Co. Ltd.Unknown
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingAcute Kidney Injury | Renal TransplantationFrance
-
University of MichiganCompletedKidney Diseases | Inflammation | Covid19 | SARS-CoV InfectionUnited States
-
Shirley Ryan AbilityLabEnrolling by invitationSpinal Cord Injuries | Acute Spinal Cord InjuryUnited States
-
University Hospital, Clermont-FerrandUniversité d'Auvergne; Association des Médecins des Urgences de Clermont-FerrandCompletedBiomarkers of Stress in Emergency PhysiciansFrance